News Column

Studies from Institute of Chemical Technology Have Provided New Information about Colitis

May 28, 2014

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Digestive System Diseases and Conditions. According to news reporting originating in Mumbai, India, by NewsRx journalists, research stated, "Inflammatory bowel diseases, which largely comprise ulcerative colitis (UC) and Crohn's disease, are increasingly posing as a global threat because of the incompetence of the current therapy in the entire patient population. This necessitates the identification of alternative therapeutic molecules or their combinations, which may serve as effective first-line or maintenance therapeutics."

The news reporters obtained a quote from the research from the Institute of Chemical Technology, "In this quest, celecoxib, a selective cyclooxygenase-2 inhibiting nonsteroidal anti-inflammatory agent and curcumin, a natural antioxidant and anti-inflammatory agent, have both been found to be useful in alleviating UC. Furthermore, studies involving their combination have proved synergistic action of these two agents. In the current investigation, we have formulated pH-sensitive nanoparticles of curcumin-celecoxib combination as a potential therapy for UC. Synergistic action of the drug combination, delivery advantages of nanosized carriers, and pH-sensitive nature of the polymer were collectively hypothesized to reduce the overall toxicity and total dose of celecoxib and provide enhanced efficacy for mitigating UC. The hypothesis was confirmed in a UC model in rats, where pH-sensitive nanoparticles of the drug combination were found to be more efficacious than nanoparticles of either drugs or drug/s suspension."

According to the news reporters, the research concluded: "Further, the blank nanoparticles did not exhibit any therapeutic effect, thereby confirming efficacy of the drug combination for treating UC."

For more information on this research see: pH-sensitive nanoparticles of curcumin-celecoxib combination: evaluating drug synergy in ulcerative colitis model. Journal of Pharmaceutical Sciences, 2014;103(2):687-96. (Wiley-Blackwell -; Journal of Pharmaceutical Sciences -

Our news correspondents report that additional information may be obtained by contacting D. Gugulothu, Dept. of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai, 400019, India. Additional authors for this research include A. Kulkarni, V. Patravale and P. Dandekar (see also Digestive System Diseases and Conditions).

Keywords for this news article include: Asia, India, Mumbai, Alkanes, Therapy, Curcumin, Catechols, Hydrocarbons, Nanoparticle, Nanotechnology, Diarylheptanoids, Gastroenterology, Organic Chemicals, Ulcerative Colitis, Emerging Technologies, Digestive System Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters